AN INTERNATIONAL OBSERVATIONAL STUDY TO ASSESS THE USE OF SORAFENIB AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS

被引：1
|
作者：
Peck-Radosavljevic, M. [1 ]
Raoul, J. -L. [2 ]
Lee, H. C. [3 ]
Kudo, M. [4 ]
Nakajima, K. [5 ]
Cheng, A. -L. [6 ]
机构：
[1] Inst J Paoli I Calmettes, F-13009 Marseille, France
[2] Med Univ Vienna, Vienna, Austria
[3] Asan Med Ctr, Seoul, South Korea
[4] Kinki Univ, Sch Med, Osaka 589, Japan
[5] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31517-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1338
引用
收藏
页码：S858 / S858
页数：1
相关论文
共 50 条
  • [21] Trial Results for Sunitinib and Transarterial Chemoembolization (TACE) in Inoperable Hepatocellular Carcinoma (HCC)
    Wu, Y. V.
    Tomaszewski, G. M.
    Fetterly, G. J.
    Kuvshinoff, B.
    Groman, A.
    Wilkinson, N. W.
    Khushalani, N. I.
    Iyer, R. V.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S114 - S115
  • [22] Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
    Yao, Wang
    Xue, Miao
    Lu, Mingjian
    Wang, Yu
    Zhao, Yue
    Wu, Yanqin
    Fan, Wenzhe
    Li, Jiaping
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
    Ding, X.
    Sun, W.
    Chen, J.
    Li, W.
    Shen, Y.
    Guo, X.
    Teng, Y.
    Liu, X.
    Li, W.
    ANNALS OF ONCOLOGY, 2020, 31 : S1306 - S1306
  • [24] Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
    Ren, Baosheng
    Wang, Wansheng
    Shen, Jian
    Li, Wanci
    Ni, Caifang
    Zhu, Xiaoli
    JOURNAL OF CANCER, 2019, 10 (05): : 1189 - 1196
  • [25] Transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma - a useful tool ?
    Meister, Tobias
    Heinzow, Hauke
    Lenz, Philipp
    Ullerich, Hansjoerg
    Domschke, Wolfram
    Domagk, Dirk
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S129 - S130
  • [26] Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
    Zhao, Shoujie
    Dou, Weijia
    Fan, Qingling
    Hu, Jie
    Li, Huichen
    Zhang, Xiangnan
    Zhang, Qian
    Liu, Lei
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (09)
  • [27] Stereotactic body radiotherapy (SBRT) as an alternative to transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)
    Sapir, Eli
    Tao, Yebin
    Parikh, Neehar D.
    Bazzi, Latifa
    Devlin, Pauline
    Novelli, Paula M.
    Cuneo, Kyle Clifford
    Lawrence, Theodore Steven
    Schipper, Matthew J.
    Feng, Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma (HCC) undergoing Transarterial Chemoembolization (TACE)
    McNally, M. E.
    Martinez, A.
    Malhotra, L.
    Bloomston, M.
    Schmidt, C. R.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S33 - S33
  • [29] Transarterial chemoembolization (TACE) with doxorubicin eluting beads (DEB) for the treatment of hepatocellular carcinoma (HCC)
    Vit, A.
    De Pauli, F.
    Sponza, M.
    Mazzer, M.
    Foltran, L.
    Montanari, M.
    Piccoli, G.
    Fasola, G.
    Gasparini, D.
    Aprile, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Doxorubicin eluting bead (DEB) transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC)
    De Pauli, Federica
    Vit, Alessandro
    Aprile, Giuseppe
    Sponza, Massimo
    Iaiza, Emiliana
    Zanon, Elisa
    Piccoli, Gianluca
    Marzio, Andrea
    Giovannoni, Mariella
    Fasola, Gianpiero
    Gasparini, Daniele
    ANNALS OF ONCOLOGY, 2007, 18 : 9 - 9
12345